DOI: NO DOI Assigned
Muhammad Ehsan Jalil', M Muhibur Rahman¹, Md. Saiful Islam, Muhammad Abdur Razzak, Abu Noim Md Abdul Hai
Hyperphosphataemia is associated with various adverse effects. Its management is a challenge to maintain a good quality of life in a patient chronic kidney disease (CKD) with maintenance haemodialysis (MHD). Currently it is managed by maintaining adequate haemodialysis (HD), reducing circulating level of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetics. There is no baseline study in Bangladeshi patients who are getting the management of chronic kidney disease- bone mineral derangement CKD-MBD) according to guideline given by Kidney Disease Outcome Quality Initiative (K/DOQI). So this study aims to determine the serum phosphate level in haemodialysis patients in Bangladesh according the target range of K/DOQ! This study was a cross sectional observational study conducted in the haemodialysis unit of National Institute of Kidney Disease and Urology (NIKDU) and Bangladesh Institute of Research & Rehabilitation on Diabetes, Endocrine and Metabolism (BIRDEM). The patients getting maintenance haemodialysis in National Institute of Kidney Disease and Urology (NIKDU) and also Bangladesh Institute of Research & Rehabilitation on Diabetes, Endocrine and Metabolism (BIRDEM) were enrolled in this study. Laboratory findings of the study patients, it was observed that the percentages of patients (drug history related to phosphate binder) who received dialyus twice & thrice per week and within the target range of serum levels were as follows serum phoxplate: 41.1% & 39.1% respectively and patients (no drug history related to phosphate binder) who recened dialysis twice & thrice per week and within the target range of serum levels were as follows serum phosphate: 33.3% & 46.2% respectively. The patients (no drug history related vinamin D) who received dialysis twice & thrice per week and within the target range of serum levels were as jollows serum phosphate 423 & 42.4% respectively. More than a half of the patients presented with experphosphataemia and half of the patients presented with below the target range of ratherine in respect to the degree of achievement of the status of serum phosphate and parathyread hormone level according to K/DOQI guidelines in maintenance haemodialysis patients.